Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study

Date

08 Oct 2016

Session

Poster Display

Presenters

Jean-Marie Michot

Citation

Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375

Authors

J. Michot1, P. Armand2, W. Ding3, V. Ribrag1, B. Christian4, A. Balakumaran5, P. Marinello5, S. Chlosta5, Y. Zhang5, M. Shipp2, P.L. Zinzani6

Author affiliations

  • 1 Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Oncology, Dana-Farber Cancer Institute, Boston/US
  • 3 Oncology, Mayo Clinic, Rochester/US
  • 4 Internal Medicine, The Ohio State University, Columbus/US
  • 5 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 6 Oncology, Università di Bologna, Bologna/IT
More

Resources

Abstract 3239

Background

The PD-L1/PD-1 pathway may be an important mechanism of tumor immune escape in hematologic malignancies. In the multicohort, phase 1b KEYNOTE-013 study of pembrolizumab (pembro) in patients with hematologic malignancies, pembro was associated with a tolerable safety profile and a promising objective response rate (ORR, 40% [4/10]) in patients with rrPMBCL. In the phase 2 MC1485 study in patients with chronic lymphocytic leukemia (CLL) including RS, pembro showed promising preliminary efficacy (ORR, 43% [3/7]) in patients with rrRS. The open-label, multicenter, phase 2 KEYNOTE-170 study (NCT02576990) was designed to further evaluate the safety and efficacy of pembro in patients with rrPMBCL and rrRS.

Trial design

Eligible patients must be aged ≥18 years and have either (1) diagnosis of rrPMBCL according to WHO 2008 criteria, failed to achieve a complete response (CR) or relapsed after autologous stem-cell transplantation (auto-SCT), or are ineligible for auto-SCT and have failed to respond or relapsed after ≥2 lines of prior treatment; or (2) pathologic diagnosis per local institutional review of rrRS that transformed from underlying CLL, have received at ≥1 prior therapy for rrRS, and have relapsed or refractory disease. Patients are to receive pembro 200 mg intravenously every 3 weeks for up to 35 cycles or until disease progression or unacceptable toxicity. In patients with rrRS, additional standard therapies to treat the underlying CLL may be added at the physician's discretion. Eligible patients who attain a CR as determined by the independent central imaging vendor may stop trial treatment and would be eligible for retreatment if they experience disease progression. Response is to be assessed every 12 weeks by independent central imaging vendor review based on International Working Group (IWG) response criteria. The primary end point is ORR by independent central imaging vendor according to IWG response criteria or IWG response criteria with special considerations for RS; secondary end points include PFS, OS, and safety and tolerability. Enrollment will continue until ∼106 patients have been enrolled.

Clinical trial identification

NCT02576990

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Disclosure

J-M. Michot: Advisory board member Bristol Myers Squibb. W. Ding: Corporate-sponsored research: Merck, research funding. A. Balakumaran, P. Marinello, S. Chlosta, Y. Zhang: Employee of Merck & Co, Inc. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings